Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Key Stats

• Today's Range: $10.07 to $10.63
• 50-Day Range: $9.28 to $13.30
• 52-Week Range: $9.20 to $21.48
• Volume: 846,735 shs
• Average Volume: 498,534 shs
• Market Capitalization: $609.53 million
• P/E Ratio: 11.59
• Dividend Yield: 5.75%
• Price Target: $19.33
• Consensus Rating: Hold

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 84% of companies evaluated by MarketBeat, and ranked 155th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Embecta has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Embecta has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 7.72%

Earnings Growth

Earnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 11.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.96.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 11.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.00.

Price to Earnings Growth Ratio

Embecta has a PEG Ratio of 0.64. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.13% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Embecta has recently increased by 61.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

Embecta is a leading dividend payer. It pays a dividend yield of 5.98%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 66.67%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.13% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Embecta has recently increased by 61.90%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for EMBC on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have bought more of their company's stock than they have sold. Specifically, they have bought $106,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.42% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EMBC Stock Analysis - Frequently Asked Questions

How have EMBC shares performed this year?

Embecta's stock was trading at $20.65 at the beginning of the year. Since then, EMBC shares have decreased by 49.5% and is now trading at $10.43.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) announced its quarterly earnings data on Friday, May, 9th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.04. The business's revenue was down 9.8% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Embecta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/09/2025
• Record date for 6/13 Dividend: 5/28/2025
• Ex-Dividend for 6/13 Dividend: 5/28/2025
• Dividend Payable: 6/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:EMBC
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 2,100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Embecta: $19.33
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: +85.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.90
• Trailing P/E Ratio: 11.59
• Forward P/E Ratio: 3.66
• P/E Growth: 0.64
• Net Income: $78.30 million
• Net Margins: 4.89%
• Pretax Margin: 5.10%
• Return on Equity: -19.67%
• Return on Assets: 12.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.48
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 0.54
• Cash Flow: $3.47 per share
• Price / Cash Flow: 3.01
• Book Value: ($12.80) per share
• Price / Book: -0.81

Miscellaneous

• Outstanding Shares: 58,440,000
• Free Float: 58,198,000
• Market Cap: $609.53 million
• Optionable: Optionable
• Beta: 1.08